Stuttgart - Delayed Quote EUR

Lineage Cell Therapeutics Inc (BT3.SG)

0.9150

+0.0050

+(0.55%)

As of July 23 at 10:00:00 PM GMT+2. Market Open.

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium

CARLSBAD, Calif., April 22, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the Christopher & Dana Reeve Foundation, a non-profit organization dedicated to advancing innovative research and improving quality of life for individuals impacted by paralysis, are proud to collaborate and present the 3rd Annual Spinal Cord Injury Investor Symposium ("3rd SCIIS"). This year’s e

Business Wire 2 days ago

LCTX
Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)

CARLSBAD, Calif., April 21, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, has been invited to join presenters from REGENXBIO Inc., Regenerative Patch Technologies, LLC, Neurotech Pharmaceuticals, Inc., and others, as part of the "I Shall Be Released: Novel Drug Delivery Approaches for Glaucoma and Ret

Business Wire 3 days ago

LCTX
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

CARLSBAD, Calif., March 10, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today reported its fourth quarter and full year 2024 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.

Business Wire last month

LCTX
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

CARLSBAD, Calif., March 05, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its fourth quarter and full year 2024 financial and operating results on Monday, March 10, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Monday, March 10, 2025, at 4:30 p.m. E

Business Wire last month

LCTX
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury

CARLSBAD, Calif., February 11, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, announced today that the Company has initiated the DOSED (Delivery of Oligodendrocyte Progenitor Cells (OPCs) for Spinal Cord Injury: Evaluation of a Novel Device) clinical study. The DOSED study will evaluate the safety and utility of the Manual Inject Parenchymal Spinal Delivery Syst

Business Wire 2 months ago

LCTX
Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference

CARLSBAD, Calif., February 04, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the Oppenheimer 35th Annual Healthcare Lifesciences Conference on February 11, 2025 at 12:40pm ET. The conference is being held virtually February 11-12, 2025.

Business Wire 2 months ago

LCTX
Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering

CARLSBAD, Calif., January 27, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the closing of the second tranche of its previously announced registered direct offering of an aggregate of up to $66 million. The Company had previously received $24 million in gross proceeds at the closing of the first tranche in November 2024. Today, the Company received an addit

Business Wire 2 months ago

LCTX
Lineage Cell Therapeutics Issues Letter to Stockholders

CARLSBAD, Calif., January 06, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today published a letter to shareholders highlighting the company’s recent achievements and outlook for 2025.

Business Wire 3 months ago

LCTX
Lineage Cell price target lowered to $2 from $3 at D. Boral Capital

D. Boral Capital lowered the firm’s price target on Lineage Cell Therapeutics (LCTX) to $2 from $3 and keeps a Buy rating on the shares. The firm adjusted the company’s model for the new shares. The analyst says Lineage enters 2025 with “strong” operational progress, bolstered by a recent capital raise that extends its cash runway to support ongoing clinical trials and development programs. Key catalysts in the year ahead include pivotal updates from the OpRegen program for dry age-related macul

TipRanks 3 months ago

LCTX
Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering

CARLSBAD, Calif., November 21, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the first closing of its previously announced registered direct offering for the purchase and sale of up to an aggregate of 39,473,688 of Lineage’s common shares and accompanying warrants (the "common warrants") to purchase an aggregate of up to 39,473,688 of Lineage’s common share

Business Wire 4 months ago

LCTX
Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering

CARLSBAD, Calif., November 20, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it entered into definitive agreements with certain healthcare focused institutional investors and with Broadwood Partners, L.P. ("Broadwood"), an affiliate of Neal Bradsher, a member of Lineage’s board of directors, for the purchase and sale of up to an aggregate of 39,473,688

Business Wire 5 months ago

LCTX
Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

CARLSBAD, Calif., November 14, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its third quarter 2024 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.

Business Wire 5 months ago

LCTX
Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

CARLSBAD, Calif., November 07, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, November 14, 2024, at 4:30 p.m. Eastern Time/1:

Business Wire 5 months ago

LCTX
Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit

CARLSBAD, Calif., October 14, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the Maxim Group 2024 Virtual Healthcare Summit, in a fireside chat hosted by Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research. Lineage’s fireside chat will be available for

Business Wire 6 months ago

LCTX
OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium

CARLSBAD, Calif., September 25, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium, PSC-Derived Cell Therapies: Clinical Advances, NextGen Technologies, and the Path to Success. Mr. Culley

Business Wire 6 months ago

LCTX
Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop

CARLSBAD, Calif., September 18, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported that preclinical results with ReSonance (ANP1), the Company’s auditory neuronal cell transplant for the treatment of hearing loss, were presented at the 59th Annual Inner Ear Biology Workshop by Ofer Wiser, Ph.D. Senior Scientist, Technological Innovation at Cell Cure Neurosciences

Business Wire 7 months ago

LCTX
Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

CARLSBAD, Calif., August 13, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference being held on Thursday, August 15, 2024. Lineage’s presentation will be available for viewing on-demand, beginning on Thursday, August 15, 20

Business Wire 8 months ago

LCTX
Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

CARLSBAD, Calif., August 08, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its second quarter 2024 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.

Business Wire 8 months ago

LCTX
Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

CARLSBAD, Calif., August 01, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its second quarter 2024 financial and operating results on Thursday, August 8, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, August 8, 2024, at 4:30 p.m. Eastern Time/1:30 p.m.

Business Wire 8 months ago

LCTX
Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index

CARLSBAD, Calif., July 02, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has been added as a member of the broad-market Russell 3000® Index, effective after the U.S. market opens on July 1, 2024, as part of the 2024 Russell indexes reconstitution. The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of

Business Wire 9 months ago

LCTX